Vilum I A

Balykina Y.E., Vilum I.A., Kolbin A.S., Proskurin M.A. 1031

It is the first time a comparative pharmacoeconomic analysis of telavancin (Vibativ®) use for treatment of patients suffering from nosocomial infections caused by resistant bacterial flora using the example of patients with nosocomial pneumonia was performed in Russia. The study was carried out using mathematical modelling with a one-month horizon. Cost-benefit analysis, budget-impact analysis, and sensitivity analysis were used. The study found that telavancin use showed high clinical efficacy and one of the best safety profiles among other medical treatment technologies for such groups of patients. Telavancin use makes economic sense in terms of cost-efficacy ratio as compared to vancomycin and linezolid. According to the results of analysis of budget impact, for wide use estimated strategy requires additional investment to the extent of 13% when compared with the strategies of the use of vancomycin and linezolid.

Balykina Y.E., Vilum I.A., Kolbin A.S., Proskurin M.A. 1022

It is the first time a comparative pharmacoeconomic analysis of telavancin (Vibativ®) use for treatment of patients suffering from nosocomial infections caused by resistant bacterial flora using the example of patients with complicated skin and soft tissue infections was held. The study was carried out using mathematical modelling with a one-month horizon. Cost-benefit analysis, budget-impact analysis, and sensitivity analysis were used. The study found that telavancin use showed high clinical efficacy and one of the best safety profiles among other medical treatment technologies for such groups of patients. Telavancin use makes more economic sense in terms of cost-efficacy ratio than daptomycin, tigecycline and linezolid. Telavancin use is more advantageous in terms of budget impact analysis as compared to linezolid and daptomycin use: saving up to 32,705,178 rubles from the budget, which enables to treat up to 126 more patients.

Balykina Y.E., Vilum I.A., Kolbin A.S., Proskurin M.A. 1022

It is the first time a comparative pharmacoeconomic analysis of telavancin (Vibativ®) use for treatment of patients suffering from nosocomial infections caused by resistant bacterial flora using the example of patients with complicated skin and soft tissue infections was held. The study was carried out using mathematical modelling with a one-month horizon. Cost-benefit analysis, budget-impact analysis, and sensitivity analysis were used. The study found that telavancin use showed high clinical efficacy and one of the best safety profiles among other medical treatment technologies for such groups of patients. Telavancin use makes more economic sense in terms of cost-efficacy ratio than daptomycin, tigecycline and linezolid. Telavancin use is more advantageous in terms of budget impact analysis as compared to linezolid and daptomycin use: saving up to 32,705,178 rubles from the budget, which enables to treat up to 126 more patients.

Balykina Y.E., Vilum I.A., Kolbin A.S., Proskurin M.A. 1031

It is the first time a comparative pharmacoeconomic analysis of telavancin (Vibativ®) use for treatment of patients suffering from nosocomial infections caused by resistant bacterial flora using the example of patients with nosocomial pneumonia was performed in Russia. The study was carried out using mathematical modelling with a one-month horizon. Cost-benefit analysis, budget-impact analysis, and sensitivity analysis were used. The study found that telavancin use showed high clinical efficacy and one of the best safety profiles among other medical treatment technologies for such groups of patients. Telavancin use makes economic sense in terms of cost-efficacy ratio as compared to vancomycin and linezolid. According to the results of analysis of budget impact, for wide use estimated strategy requires additional investment to the extent of 13% when compared with the strategies of the use of vancomycin and linezolid.